News
Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 trial Of Acoramidis In ATTR-CM
8 Apr 24
News
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70
19 Mar 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $60
11 Mar 24
News, Price Target, Analyst Ratings
BridgeBio Pharma Prices Public Offering Of 8,620,690 Common Shares At $29/Share
6 Mar 24
News
Mizuho Maintains Buy on BridgeBio Pharma, Lowers Price Target to $53
5 Mar 24
News, Price Target, Analyst Ratings
What's Going On With BridgeBio Pharma Stock On Monday?
4 Mar 24
Biotech, News, Health Care, Contracts, Movers, General
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $47 Price Target
4 Mar 24
News, Price Target, Reiteration, Analyst Ratings
BridgeBio Pharma And Bayer Announce European Licensing Agreement For Acoramidis In ATTR-CM, BridgeBio To Receive $310M Plus Royalties
4 Mar 24
News
Recap: BridgeBio Pharma Q4 Earnings
22 Feb 24
Earnings
BridgeBio Pharma Q4 EPS $(0.96) Misses $(0.91) Estimate, Sales $1.75M Down From $1.87M YoY
22 Feb 24
Earnings, News
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
15 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
BridgeBio, Kyowa Kirin Ink Partnership With An Upfront Payment Of $100M For Exclusive License On Infigratinib In Skeletal Dysplasias In Japan
7 Feb 24
News, Contracts
BMO Capital Initiates Coverage On BridgeBio Pharma with Market Perform Rating, Announces Price Target of $37
31 Jan 24
News, Price Target, Initiation, Analyst Ratings
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
30 Jan 24
News
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $47
29 Jan 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $50 Price Target
22 Jan 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10 Apr 24
Press Releases
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
7 Apr 24
Health Care, Press Releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
20 Mar 24
Markets, Press Releases
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
5 Mar 24
Press Releases
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
4 Mar 24
News, Health Care, IPOs, Press Releases
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
4 Mar 24
Press Releases
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22 Feb 24
Earnings, Press Releases
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
7 Feb 24
Health Care, Press Releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
6 Feb 24
Press Releases
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
5 Feb 24
Health Care, Press Releases
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
2 Feb 24
Press Releases
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
30 Jan 24
Press Releases